

Anti-IL-23α (Guselkumab), Human IgG1 Antibody

06/20

CATALOG NO.:

A2147-100 (100 µg)

BACKGROUND DESCRIPTION: Guselkumab is a fully human IgG1 lambda monoclonal antibody that is produced in Chinese Hamster Ovary (CHO) cells. This monoclonal antibody selectively inhibits IL-23 by binding to the p19 subunit of IL-23, blocking its interaction with the receptor (IL-23R), and inhibiting the release of proinflammatory chemokines and cytokines. The antibody was developed by Janssen Biotech and received FDA approval for the treatment of moderate to severe plaque psoriasis. Guselkumab is marketed under the trade name TREMFYA®.

ALTERNATE NAMES:	CNTO1959, CNTO-1959, TREMFYA, IL23α, IL 23α
ANTIBODY TYPE:	Monoclonal
CONCENTRATION:	1 mg/ml
HOST/ISOTYPE:	Human / IgG1, lambda
SOURCE:	CHO cells
IMMUNOGEN:	Guselkumab
MOLECULAR WEIGHT:	143.6 kDa
PURIFICATION:	Protein A purified
FORM:	Liquid
FORMULATION:	In PBS, pH 7.5
SPECIES REACTIVITY:	Human
STORAGE CONDITIONS:	Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-TNF- α (Certolizumab Pegol), Humanized Antibody (A2142) Anti-TNF- α (Adalimumab), humanized Antibody (A1048) Anti-TNF- α (Golimumab), Human IgG1 Antibody (A2141) Anti-TNF alpha (Infliximab), Human IgG1 Antibody (A1097) Anti-IL12B (Ustekinumab), Human IgG1 Antibody (A2137)

FOR RESEARCH USE ONLY! Not to be used on humans.

